News Releases

Month Year

Su	Mo	Tu	We	Th	Fr	Sa
25	26	27	28	29	30	1
2	3	4	5	6	7	8
9	10	11	12	13	14	15
16	17	18	19	20	21	22
23	24	25	26	27	28	29
30	31	1	2	3	4	5

Cancel Go

Month Year

Su	Mo	Tu	We	Th	Fr	Sa
25	26	27	28	29	30	1
2	3	4	5	6	7	8
9	10	11	12	13	14	15
16	17	18	19	20	21	22
23	24	25	26	27	28	29
30	31	1	2	3	4	5

Cancel Go

Email Alerts

Year All Years 2024 2023 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011 2010 2009 2008 2007 2006 2005 2004 2003 2002 Keywords Go

Advanced Search

Keywords

  Search Headlines Only

From

To

Asset Types

 Photos  Video  Audio  Documents  Events  Standard

 Basic Search

• Feb 19, 2014

  Insmed Provides Interim Update from Two-Year, Open-Label Extension Study of ARIKACE to Treat Pseudomonas aeruginosa in Cystic Fibrosis Patients

  Initial 12-Month Data Demonstrate Long-Term Safety and Durability of Effect
• Feb 10, 2014

  ARIKACE to Receive Orphan Medicinal Product Designation in the European Union to Treat Lung Infections Caused by Nontuberculous Mycobacteria
• Feb 4, 2014

  Insmed to Present at the Leerink Swann Global Healthcare Conference
• Feb 4, 2014

  Insmed to Present at the Leerink Swann Global Healthcare Conference
• Nov 5, 2013

  Insmed Reports Third Quarter 2013 Financial Results
• Nov 1, 2013

  Insmed Appoints David W.J. McGirr to Its Board of Directors
• Oct 23, 2013

  Insmed to Host Third Quarter 2013 Financial Results Conference Call on Tuesday, November 5, 2013
• Oct 15, 2013

  Insmed Completes Enrollment of Phase 2 Clinical Trial of ARIKACE to Treat Nontuberculous Mycobacteria Lung Disease in U.S. and Canada
• Sep 15, 2013

  Insmed to Present at Leerink Swann Rare Disease Roundtable
• Sep 11, 2013

  Insmed Fortifies Global Patent Portfolio
• Sep 4, 2013

  Insmed to Participate in the Stifel Healthcare Conference 2013
• Aug 7, 2013

  Insmed to Participate in August Investor Conferences
• Aug 6, 2013

  Insmed Reports Second Quarter Financial Results
• Jul 31, 2013

  Insmed to Host Second Quarter 2013 Financial Results Conference Call on Tuesday, August 6, 2013
• Jul 29, 2013

  Insmed Appoints Christine Pellizzari as General Counsel and Corporate Secretary
• Jul 22, 2013

  Insmed Announces Closing of Public Offering and Exercise of Option to Purchase Additional Shares
• Jul 17, 2013

  Insmed Announces Pricing of Public Offering of Common Stock
• Jul 15, 2013

  Insmed Announces Proposed Public Offering of Common Stock
• Jul 8, 2013

  Insmed to Present at the 8th Annual JMP Securities Healthcare Conference
• Jul 1, 2013

  ARIKACE Meets Primary Endpoint of Non-Inferiority to TOBI in Phase 3 Clinical Trial in Europe and Canada to Treat Pseudomonas aeruginosa in Cystic Fibrosis Patients

  ARIKACE Receives Qualified Infectious Disease Product and Fast Track Designations from the U.S. FDA for the Treatment of Non-Tuberculous Mycobacteria Lung Infections
• Jun 28, 2013

  Insmed to Join the Russell Global(R) and Russell 3000(R) Indexes
• Jun 28, 2013

  Insmed to Report Top-Line Results From Phase 3 Clinical Trial of ARIKACE to Treat Pseudomonas Aeruginosa in Cystic Fibrosis
• May 14, 2013

  Insmed Granted Key Composition of Matter Patent Allowance for ARIKACE in Europe
• May 13, 2013

  Insmed to Present at the UBS Global Healthcare Conference
• May 10, 2013

  Insmed to Present at the Bank of America Merrill Lynch 2013 Health Care Conference
• May 7, 2013

  Insmed Reports First Quarter Financial Results
• May 1, 2013

  Insmed to Host First Quarter 2013 Financial Results Conference Call on Tuesday, May 7, 2013
• Apr 18, 2013

  Insmed to Present at the 12th Annual Needham Healthcare Conference
• Apr 1, 2013

  Insmed Appoints Matthew Pauls as Chief Commercial Officer
• Mar 28, 2013

  ARIKACE Receives Orphan Drug Designation for Treating Infections Caused by Non-Tuberculous Mycobacteria
• Mar 27, 2013

  Insmed to Present at Future Leaders in the Biotech Industry Conference
• Mar 18, 2013

  Insmed Reports Fourth Quarter and Full Year 2012 Financial Results
• Mar 11, 2013

  Insmed to Host Fourth Quarter and Full Year 2012 Financial Results Conference Call on Monday, March 18, 2013
• Feb 26, 2013

  Insmed to Present at Two Upcoming Investor Conferences
• Feb 6, 2013

  Insmed to Present at Two Upcoming Healthcare Investor Conferences
• Dec 13, 2012

  Insmed to Present at 31st Annual J.P. Morgan Healthcare Conference
• Nov 13, 2012

  Insmed Announces CLEAR-108 Phase 3 Clinical Study of ARIKACE® in Cystic Fibrosis Patients with Pseudomonas Lung Infections Has Completed Target Enrollment
• Nov 12, 2012

  Insmed To Present At Two Upcoming Investor Conferences
• Nov 7, 2012

  Insmed Appoints 15-Year Life Sciences Industry Veteran Andrew Drechsler as Chief Financial Officer
• Nov 7, 2012

  Insmed Announces Financial Results for Third Quarter and Nine-Months Ended September 30, 2012
• Oct 24, 2012

  Insmed to Host 2012 Third Quarter Earnings Conference Call
• Sep 28, 2012

  Insmed Announces Pricing of Approximately $26 Million Direct Public Offering
• Aug 30, 2012

  Insmed to Present at Stifel Nicolaus 2012 Healthcare Conference
• Aug 14, 2012

  Insmed to Present at 2012 Wedbush PacGrow Life Sciences Management Access Conference
• Aug 7, 2012

  Insmed Announces Financial Results For Second Quarter And Six-months Ended June 30, 2012
• Aug 6, 2012

  Pharmaceutical Industry Veteran Al Altomari Elected To Insmed's Board Of Directors
• Aug 2, 2012

  Insmed Receives Second Composition Of Matter Patent For ARIKACE®
• Jul 30, 2012

  Insmed Announces Planned Departure Of Chief Financial Officer
• Jul 24, 2012

  Insmed to Host 2012 Second Quarter Earnings Conference Call
• Jul 10, 2012

  Insmed To Present At JMP Securities 7th Annual Healthcare Conference

Show 5102550100 per page

Stay In The Loop

Want to stay up to date on our news, events, and filings? Set up your
email alerts.

Sign Up

View the latest Insmed Investor Presentation

Download